SEARCH

Search Details

Yamamoto Kazuki

Faculty of Pharmaceutical Sciences Center for Research and Education on Drug DiscoveryAssistant Professor

Researcher basic information

■ Degree
  • Doctor (Pharmaceutical sciences), Hokkaido University, Mar. 2021
■ URL
researchmap URLホームページURL■ Various IDs
ORCID IDJ-Global ID■ Research Keywords and Fields
Research Keyword
  • 有機合成化学
  • 創薬化学
  • 天然物化学
Research Field
  • Life Science, Pharmaceutical chemistry and drug development sciences, 有機合成化学
  • Life Science, Pharmaceutical chemistry and drug development sciences, 全合成
  • Life Science, Pharmaceutical chemistry and drug development sciences, 創薬化学
  • Life Science, Pharmaceutical chemistry and drug development sciences, 天然物化学
■ Educational Organization

Career

■ Career
Career
  • Oct. 2021 - Present
    Hokkaido University, Faculty of Pharmaceutical Sciences, 助教
  • Apr. 2021 - Sep. 2021
    日本学術振興会特別研究員PD
  • Apr. 2020 - Mar. 2021
    日本学術振興会特別研究員DC2
Educational Background
  • Apr. 2018 - Mar. 2021, Hokkaido University, Graduate School of Life Science, 博士後期課程
  • Apr. 2016 - Mar. 2018, Hokkaido University, Graduate School of Life Science, 修士課程
  • Apr. 2012 - Mar. 2016, Hokkaido University, Faculty of Pharmaceutical Sciences

Research activity information

■ Awards
  • Mar. 2021, 優秀発表賞 日本薬学会第141年会
    抗緑膿菌活性を示すウリジルペプチド系天然物の構造活性相関研究
    寺澤 侑馬;佐高 千里;佐藤 豊孝;山本 一貴;勝山 彬;松丸 尊紀;薬師寺 文華;横田 伸一;市川 聡, Japan society
  • May 2019, 優秀発表賞 第17回次世代を担う有機化学シンポジウム
    ツニカマイシンVの全合成と構造に基づく低毒性誘導体の創製
    山本 一貴;勝山 彬;薬師寺 文華;松丸 尊紀;市川聡, Japan society
  • Mar. 2019, 優秀発表賞 日本薬学会第139年会
    ツニカマイシンVの全合成と低毒性誘導体の創製
    山本 一貴;勝山 彬;薬師寺 文華;市川 聡, Japan society
  • Jul. 2017, Best Poster賞 第29回万有札幌シンポジウム
    Tunicamycin類の全合成研究
    山本 一貴;薬師寺 文華;市川 聡, Japan society
■ Papers
  • A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model
    Runa Takahashi; Kazuki Yamamoto; Hikaru Toya; Haruka Shoji; Kohei Kawanishi; Kyoka Momosaki; Miyuki Yabe; Ken Takashima; Ryuta Muromoto; Satoshi Ichikawa; Tadashi Matsuda; Yuichi Kitai
    Oncogene, 23 Dec. 2025
    English, Scientific journal, Abstract
    Damage-associated molecular patterns (DAMPs) are secreted from damaged or dying cells and activate innate immune signaling via pattern-recognition receptors such as Toll-like receptors and cGAS. We previously showed that topotecan, a chemotherapeutic drug and topoisomerase I (TOP1) inhibitor, binds to ribosomal protein RPL15 and induces the secretion of DAMPs from cancer cells, which activate cGAS-STING signaling in dendritic cells. RPL15-knockdown B16-F10 melanoma tumors were sensitized to anti-PD-1 antibody, suggesting that RPL15 inhibition may have the potential to improve immune checkpoint inhibitor efficacy. However, topotecan and its derivatives, including SN-38, are highly cytotoxic because of their TOP1 inhibitory activity. Here, we synthesized SN-38-conjugated pomalidomide (SN38-PROTAC) and showed that SN38-PROTAC induced ubiquitin-mediated degradation of RPL15, but not TOP1. SN38-PROTAC treatment induced DAMP secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. The cytotoxicity of SN38-PROTAC in MCF7 cells was 100-fold lower than SN-38. SN38-PROTAC treatment increased the CTL/Treg ratio in tumors and sensitized B16-F10 tumors to anti-PD-1 antibody in a mouse model. The enhanced antitumor effects of SN38-PROTAC and anti-PD-1 antibody combination were abolished in STING-deficient mice. Our results indicate that SN38-PROTAC, which induces RPL15 degradation, has the potential to enhance ICI efficacy in PD-1-resistant cancer with low cytotoxicity.
  • Design, Synthesis, and Biological Evaluation of Lipid‐Modified Derivatives of Tunicamycins
    Kazuki Yamamoto; Toyotaka Sato; Ellene H. Mashalidis; Seok‐Yong Lee; Motohiro Horiuchi; Satoshi Ichikawa
    Chemistry – A European Journal, 22 Oct. 2025
    English, Scientific journal, Abstract

    Naturally occurring antibiotic tunicamycin targets bacterial peptidoglycan biosynthesis by inhibiting bacterial phospho‐
    N
    ‐acetylmuraminic acid (MurNAc)‐pentapeptide translocase (MraY), but it also inhibits human UDP‐
    N
    ‐acetylglucosamine (GlcNAc): polyprenol phosphate translocase (GPT), leading to cytotoxicity. This study thoroughly investigated the structure‐activity relationship of the fatty acyl side chain of tunicamycin to develop MraY‐selective inhibitors, based on structural differences between MraY and GPT. Longer alkyl chains and flexible structures were found to favor MraY inhibitory activity, and benzene rings were acceptable for binding. The hybrid analogue containing oleoyl group, which contributed most significantly to MraY inhibitory activity, and the MurNAc moiety, which is important for MraY‐selective inhibition, showed enhanced MraY inhibitory activity as well as improved antibacterial activity against
    S. aureus
    and
    E. faecium
    .
  • Development of a natural product optimization strategy for inhibitors against MraY, a promising antibacterial target.
    Kazuki Yamamoto; Toyotaka Sato; Aili Hao; Kenta Asao; Rintaro Kaguchi; Shintaro Kusaka; Radhakrishnam Raju Ruddarraju; Daichi Kazamori; Kiki Seo; Satoshi Takahashi; Motohiro Horiuchi; Shin-Ichi Yokota; Seok-Yong Lee; Satoshi Ichikawa
    Nature communications, 15, 1, 5085, 5085, 14 Jun. 2024, [Lead author, Corresponding author], [International Magazine]
    English, Scientific journal, MraY (phospho-N-acetylmuramoyl-pentapeptide-transferase) inhibitory natural products are attractive molecules as candidates for a new class of antibacterial agents to combat antimicrobial-resistant bacteria. Structural optimization of these natural products is required to improve their drug-like properties for therapeutic use. However, chemical modifications of these natural products are painstaking tasks due to complex synthetic processes, which is a bottleneck in advancing natural products to the clinic. Here, we develop a strategy for a comprehensive in situ evaluation of the build-up library, which enables us to streamline the preparation of the analogue library and directly assess its biological activities. We apply this approach to a series of MraY inhibitory natural products. Through construction and evaluation of the 686-compound library, we identify promising analogues that exhibit potent and broad-spectrum antibacterial activity against highly drug-resistant strains in vitro as well as in vivo in an acute thigh infection model. Structures of the MraY-analogue complexes reveal distinct interaction patterns, suggesting that these analogues represent MraY inhibitors with unique binding modes. We further demonstrate the generality of our strategy by applying it to tubulin-binding natural products to modulate their tubulin polymerization activities.
  • Concise Synthesis of 11-Noriridoids via Pauson-Khand Reaction.
    Ryuji Kouda; Kazuki Yamamoto; Akira Katsuyama; Satoshi Ichikawa; Fumika Yakushiji
    Chemical & pharmaceutical bulletin, 72, 6, 547, 558, 2024, [Domestic magazines]
    English, Scientific journal, Iridoids, which are a class of monoterpenoids, are attractive synthetic targets due to their diversely substituted cis-fused cyclopenta[c]pyran skeletons. Additionally, various biological activities of iridoids raise the value of synthetic studies on this class of compounds. Here, our synthetic efforts toward 11-noriridoids; (±)-umbellatolide B (6), (±)-10-O-benzoylglobularigenin (9) and 1-O-pentenylaucubigenin (34) are described. For the efficient synthesis of target compounds, common synthetic intermediates (tricyclic enones 17 and 26) were prepared by the Pauson-Khand reaction. The cleavage of the acetal bond on the tricyclic enones and 1,2-reduction introduced the two hydroxy groups on the cyclopentane ring of the core scaffold. Furthermore, the C3-C4 olefin part was constructed by the syn-elimination of a thiocarbonate moiety to obtain 34. The developed synthetic routes for 6, 9, and 34 will be useful for the preparation of iridoid analogs that have a polyfunctionalized core skeleton.
  • Solid-Phase Synthesis of Nannocystin Ax and Its Analogues.
    Daiki Miyakita; Kohei Kawanishi; Akira Katsuyama; Kazuki Yamamoto; Fumika Yakushiji; Satoshi Ichikawa
    The Journal of organic chemistry, 88, 15, 11367, 11371, 04 Aug. 2023, [International Magazine]
    English, Scientific journal, Solid-phase total synthesis of nannocystin Ax (1) was disclosed. A coupling reaction between a peptide and a polyketide moiety was conducted on a solid support, and macrocyclization was achieved by Mitsunobu cyclization. The established synthetic route was efficient to prepare its analogues, which contain different types of peptide moieties.
  • Solid-Phase Total Synthesis of Sandramycin and Its Analogues
    Yuya Komatani; Kyoka Momosaki; Akira Katsuyama; Kazuki Yamamoto; Rintaro Kaguchi; Satoshi Ichikawa
    Organic Letters, 25, 3, 543, 548, American Chemical Society (ACS), 27 Jan. 2023
    Scientific journal
  • Synthesis of macrocyclic nucleoside antibacterials and their interactions with MraY.
    Takeshi Nakaya; Miyuki Yabe; Ellene H Mashalidis; Toyotaka Sato; Kazuki Yamamoto; Yuta Hikiji; Akira Katsuyama; Motoko Shinohara; Yusuke Minato; Satoshi Takahashi; Motohiro Horiuchi; Shin-Ichi Yokota; Seok-Yong Lee; Satoshi Ichikawa
    Nature communications, 13, 1, 7575, 7575, 20 Dec. 2022, [International Magazine]
    English, Scientific journal, The development of new antibacterial drugs with different mechanisms of action is urgently needed to address antimicrobial resistance. MraY is an essential membrane enzyme required for bacterial cell wall synthesis. Sphaerimicins are naturally occurring macrocyclic nucleoside inhibitors of MraY and are considered a promising target in antibacterial discovery. However, developing sphaerimicins as antibacterials has been challenging due to their complex macrocyclic structures. In this study, we construct their characteristic macrocyclic skeleton via two key reactions. Having then determined the structure of a sphaerimicin analogue bound to MraY, we use a structure-guided approach to design simplified sphaerimicin analogues. These analogues retain potency against MraY and exhibit potent antibacterial activity against Gram-positive bacteria, including clinically isolated drug resistant strains of S. aureus and E. faecium. Our study combines synthetic chemistry, structural biology, and microbiology to provide a platform for the development of MraY inhibitors as antibacterials against drug-resistant bacteria.
  • β-Hydroxylation of α-amino-β-hydroxylbutanoyl-glycyluridine catalyzed by a nonheme hydroxylase ensures the maturation of caprazamycin
    Saeid Malek Zadeh; Mei-Hua Chen; Zhe-Chong Wang; Elahe K. Astani; I-Wen Lo; Kuan-Hung Lin; Ning-Shian Hsu; Kamal Adhikari; Syue-Yi Lyu; Hsin-Ying Tsai; Yuma Terasawa; Miyuki Yabe; Kazuki Yamamoto; Satoshi Ichikawa; Tsung-Lin Li
    Communications Chemistry, 5, 1, 87, 87, Springer Science and Business Media LLC, Dec. 2022, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Abstract

    Caprazamycin is a nucleoside antibiotic that inhibits phospho-N-acetylmuramyl-pentapeptide translocase (MraY). The biosynthesis of nucleoside antibiotics has been studied but is still far from completion. The present study characterized enzymes Cpz10, Cpz15, Cpz27, Mur17, Mur23 out of caprazamycin/muraymycin biosynthetic gene cluster, particularly the nonheme αKG-dependent enzyme Cpz10. Cpz15 is a β-hydroxylase converting uridine mono-phosphate to uridine 5′ aldehyde, then incorporating with threonine by Mur17 (Cpz14) to form 5′-C-glycyluridine. Cpz10 hydroxylates synthetic 11 to 12 in vitro. Major product 13 derived from mutant Δcpz10 is phosphorylated by Cpz27. β-Hydroxylation of 11 by Cpz10 permits the maturation of caprazamycin, but decarboxylation of 11 by Mur23 oriented to muraymycin formation. Cpz10 recruits two iron atoms to activate dioxygen with regio-/stereo-specificity and commit electron/charge transfer, respectively. The chemo-physical interrogations should greatly advance our understanding of caprazamycin biosynthesis, which is conducive to pathway/protein engineering for developing more effective nucleoside antibiotics.
  • Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
    Shintaro Kusaka; Kazuki Yamamoto; Motoko Shinohara; Yusuke Minato; Satoshi Ichikawa
    Bioorganic & medicinal chemistry, 73, 117011, 117011, 26 Sep. 2022, [International Magazine]
    English, Scientific journal, The total synthesis of capuramycin (1), which is a promising anti-tubercular antibiotics, has been accomplished using Ferrier-type I reaction as a key step. This total synthesis is an alternative approach to the synthesis of capuramycin and its analogues. The 3'-O-demethyl analogue (2), which exhibits an equivalent antibacterial activity as capuramycin (1) against Mycobacterium smegmatis and Mycobacterium avium, is suggested to have potential as a lead structure of capuramycin analogues because 2 is more accessible from a synthetic view point.
  • Design, synthesis and conformation-activity relationship analysis of LNA/BNA-type 5'-O-aminoribosyluridine as MraY inhibitors.
    Shintaro Kusaka; Kazuki Yamamoto; Motoko Shinohara; Yusuke Minato; Satoshi Ichikawa
    Bioorganic & medicinal chemistry, 65, 116744, 116744, 20 Apr. 2022, [Peer-reviewed], [International Magazine]
    English, Scientific journal, It is important to understand and control the biologically active conformation in medicinal chemistry. Muraymycins and caprazamycins, which are strong inhibitors of MraY, are promising antibacterial agents with a novel mode of action. Focusing on a sugar puckering and a dihedral angle ϕ of the uridine moiety of these natural products, LNA/BNA-type 5'-O-aminoribosyluridine analogues, whose puckering of the ribose moiety are completely restricted to the N-type, were designed and synthesized as simplified MraY inhibitors. Their conformation-activity relationship was further investigated in details. The conformation-activity relationship analysis investigated in this study could be a general guideline for simplification and rational drug design of MraY inhibitory nucleoside natural products.
  • Solid-Phase Total Synthesis of Plusbacin A3
    Kazuki Takashina; Akira Katsuyama; Rintaro Kaguchi; Kazuki Yamamoto; Toyotaka Sato; Satoshi Takahashi; Motohiro Horiuchi; Shin-ichi Yokota; Satoshi Ichikawa
    Organic Letters, 24, 11, 2253, 2257, American Chemical Society (ACS), 25 Mar. 2022, [Peer-reviewed]
    Scientific journal
  • Corrigendum to "Design, synthesis and biological evaluation of simplified analogues of MraY inhibitory natural product with rigid scaffold" Bioorganic & Medicinal Chemistry 55 (2021) 116556.
    Kazuhiro Okamoto; Aoi Ishikawa; Ryotaro Okawa; Kazuki Yamamoto; Toyotaka Sato; Shin-Ichi Yokota; Kazuhiro Chiba; Satoshi Ichikawa
    Bioorganic & medicinal chemistry, 61, 116689, 116689, 07 Mar. 2022, [International Magazine]
    English
  • Design, synthesis and biological evaluation of simplified analogues of MraY inhibitory natural product with rigid scaffold
    Kazuhiro Okamoto; Aoi Ishikawa; Ryotaro Okawa; Kazuki Yamamoto; Toyotaka Sato; Shin-ichi Yokota; Kazuhiro Chiba; Satoshi Ichikawa
    Bioorganic & Medicinal Chemistry, 55, 116556, 116556, Elsevier BV, Feb. 2022, [Peer-reviewed]
    Scientific journal
  • Probiotic Aspergillus oryzae produces anti-tumor mediator and exerts anti-tumor effects in pancreatic cancer through the p38 MAPK signaling pathway
    Hiroaki Konishi; Shotaro Isozaki; Shin Kashima; Kentaro Moriichi; Satoshi Ichikawa; Kazuki Yamamoto; Chikage Yamamura; Katsuyoshi Ando; Nobuhiro Ueno; Hiroaki Akutsu; Naoki Ogawa; Mikihiro Fujiya
    Scientific Reports, 11, 1, Springer Science and Business Media LLC, Dec. 2021, [Peer-reviewed]
    Scientific journal
  • Elucidating the Structural Requirement of Uridylpeptide Antibiotics for Antibacterial Activity
    Yuma Terasawa; Chisato Sataka; Toyotaka Sato; Kazuki Yamamoto; Yukari Fukushima; Chie Nakajima; Yasuhiko Suzuki; Akira Katsuyama; Takanori Matsumaru; Fumika Yakushiji; Shin-ichi Yokota; Satoshi Ichikawa
    Journal of Medicinal Chemistry, 63, 17, 9803, 9827, American Chemical Society (ACS), 10 Sep. 2020, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Synthesis and biological evaluation of a MraY selective analogue of tunicamycins
    Kazuki Yamamoto; Toyotaka Sato; Yuta Hikiji; Akira Katsuyama; Takanori Matsumaru; Fumika Yakushiji; Shin-Ichi Yokota; Satoshi Ichikawa
    Nucleosides, Nucleotides & Nucleic Acids, 39, 1-3, 349, 364, Informa UK Limited, 20 Feb. 2020, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal
  • Tunicamycin: chemical synthesis and biosynthesis
    Kazuki Yamamoto; Satoshi Ichikawa
    The Journal of Antibiotics, 72, 12, 924, 933, Springer Science and Business Media LLC, Dec. 2019, [Peer-reviewed], [Lead author], [Domestic magazines]
    English, Scientific journal
  • Structural requirement of tunicamycin V for MraY inhibition
    Kazuki Yamamoto; Akira Katsuyama; Satoshi Ichikawa
    Bioorganic & Medicinal Chemistry, 27, 8, 1714, 1719, Elsevier BV, Apr. 2019, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal
  • GlcNAc-1-P-transferase–tunicamycin complex structure reveals basis for inhibition of N-glycosylation
    Jiho Yoo; Ellene H. Mashalidis; Alvin C. Y. Kuk; Kazuki Yamamoto; Benjamin Kaeser; Satoshi Ichikawa; Seok-Yong Lee
    Nature Structural & Molecular Biology, 25, 3, 217, 224, Springer Science and Business Media LLC, Mar. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • Total Synthesis of Tunicamycin V
    Kazuki Yamamoto; Fumika Yakushiji; Takanori Matsumaru; Satoshi Ichikawa
    Organic Letters, 20, 1, 256, 259, American Chemical Society (ACS), 05 Jan. 2018, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal
■ Other Activities and Achievements
■ Books and other publications
■ Lectures, oral presentations, etc.
  • 抗緑膿菌活性を示すウリジルペプチド系天然物の構造活性相関研究
    寺澤 侑馬; 佐高 千里; 佐藤 豊孝; 山本 一貴; 勝山 彬; 松丸 尊紀; 薬師寺 文華; 横田 伸一; 市川 聡
    日本薬学会第141年会, Mar. 2021, Oral presentation
  • ツニカマイシンVの全合成と構造に基づく低毒性誘導体の創製
    山本 一貴; 勝山 彬; 薬師寺 文華; 松丸 尊紀; 市川聡
    第17回次世代を担う有機化学シンポジウム, May 2019, Oral presentation
  • ツニカマイシンVの全合成と低毒性誘導体の創製
    山本 一貴; 勝山 彬; 薬師寺 文華; 市川 聡
    日本薬学会第139年会, Mar. 2019, Oral presentation
  • Tunicamycin Vの全合成と構造に基づいたMraY選択的阻害剤への変換
    山本 一貴; 市川 聡
    第60回天然有機化合物討論会, Sep. 2018, Oral presentation
  • Tunicamycin Vの全合成
    山本 一貴; 薬師寺 文華; 市川 聡
    第28回万有福岡シンポジウム, May 2018, Poster presentation
    [Invited]
  • Tunicamycin類の全合成研究
    山本 一貴; 薬師寺 文華; 市川 聡
    第29回万有札幌シンポジウム, Jul. 2017, Poster presentation
  • Tunicamycin類の全合成研究
    山本 一貴; 市川 聡
    日本薬学会第137年会, Mar. 2017, Oral presentation
■ Syllabus
  • 創薬化学特論, 2024年, 修士課程, 生命科学院
  • ドラッグデザイン演習, 2024年, 学士課程, 薬学部
  • 有機化学Ⅵ, 2024年, 学士課程, 薬学部
  • 有機化学実習Ⅰ, 2024年, 学士課程, 薬学部
  • 有機化学実習Ⅱ, 2024年, 学士課程, 薬学部
■ Affiliated academic society
  • 有機合成化学協会
  • 日本薬学会
■ Research Themes
  • 天然物誘導体ライブラリー合成戦略の適用拡大を目指した改良と抗菌活性天然物への応用
    科学研究費助成事業
    01 Apr. 2024 - 31 Mar. 2027
    山本 一貴
    日本学術振興会, 若手研究, 北海道大学, 24K18248
  • 天然物創薬を加速するライブラリー合成戦略に基づく新規抗菌薬リードの開発研究
    科学研究費助成事業 研究活動スタート支援
    31 Aug. 2022 - 31 Mar. 2024
    山本 一貴
    日本学術振興会, 研究活動スタート支援, 北海道大学, 22K20704
  • 構造活性相関研究を超高速化する天然物創薬手法の開発と抗薬剤耐性菌薬リードの創製
    科学研究費助成事業 特別研究員奨励費
    24 Apr. 2020 - 31 Mar. 2022
    山本 一貴
    本研究課題では、天然物を基盤として新規抗菌薬リードを開発するため、天然物を2つのフラグメントに分割し、アッセイプレート上で連結することで、迅速に誘導体ライブラリーを構築する方法を開発する。フラグメントの連結反応として、副生成物が生物活性評価に影響を与えない水のみであり、反応が定量的に進行するヒドラゾン形成反応を利用することとした。細菌細胞壁のペプチドグリカン生合成酵素の一つであるMraYを阻害するツニカマイシンおよびムライマイシンを基に、コアアルデヒドフラグメント4種とヒドラジンフラグメント98種を合成し、これらのDMSO溶液をアッセイプレート上で混合、濃縮することで連結反応を行い、合計392種のヒドラゾン誘導体を合成した。合成した全てのヒドラゾンの形成効率を調べるため、LC-MS解析を行った結果、コアの構造に依らず90%ほどはほとんど定量的に反応が進行していた。反応効率が悪いものに関しては、ヒドラジンフラグメントの構造に依存することがわかった。続いて、合成したヒドラゾンライブラリー全てのMraY阻害活性、抗菌活性を評価した。その結果、MraY阻害活性の高い誘導体がいくつか得られた。また抗菌活性はMraY阻害活性とある程度相関していたものの、MraY阻害活性が高いにも関わらず、抗菌活性が全くない誘導体もあった。酵素系だけでなく細胞系での評価も行ったことで、膜透過性も加味した評価を行うことができた。また、天然物がグラム陽性菌にのみ効果があるのに対して、いくつかのヒドラゾン誘導体はグラム陰性菌にも効果があった。続いて、ヒドラゾン結合は加水分解の恐れがあるため、化学的、代謝的により安定なアミド結合へと置き換えた誘導体を合成した。これらのMraY阻害、抗菌活性は、ヒドラゾンライブラリーから得られた結果とよく一致していた。
    日本学術振興会, 特別研究員奨励費, 北海道大学, 20J12016